Integra LifeSciences Holdings Corporation announced the publication of a new economic study in the Journal of Comparative Effectiveness Research, highlighting the cost-saving benefits of its DuraSeal Polyethylene Glycol (PEG) hydrogel dural sealant. The evaluation assessed the budget impact of switching from fibrin glue to DuraSeal in posterior fossa surgery across five major European countries: Belgium, France, Germany, Italy, and the United Kingdom.
The study demonstrated average cost savings ranging from €419 to €1,279 per patient when using Integra’s DuraSeal PEG hydrogel. This translates to a consistent cost reduction per procedure of approximately 22%, with Italy showing a 15% reduction. These savings are primarily attributed to DuraSeal's effectiveness in preventing cerebrospinal fluid (CSF) leaks, which are a significant cause of longer hospital stays and costly post-surgical interventions.
The findings reinforce DuraSeal's value proposition for healthcare professionals and systems, supporting Integra's neuro access and repair strategy. The clinical effectiveness and economic benefits of DuraSeal are expected to enhance its competitive positioning and potentially increase market access and adoption in the European market, despite its higher upfront cost.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.